Role of Whole-Body <sup>18</sup>F-FDG PET/CT in Screening for Metastases in Newly Diagnosed Sinonasal Malignancies

Öztürk, Kerem; Gencturk, Mehmet; Rischall, Matthew; Caicedo-Granados, Emiro; Li, Faqian; Cayci, Zuzan

doi:10.2214/ajr.18.20311

Cited by 6 publications

(6 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study found that sinonasal undifferentiated carcinoma (SNUC) had the highest mean SUVmax of 14.2, followed by adenocarcinoma with a mean SUVmax of 9.9 [93]. Whole-body 18 FDG PET/CT is a very useful method as a screening tool for the detection of distant metastasis and regional lymphatic metastases in sinonasal neoplasms and may be performed as part of the routine pretreatment evaluation of metastatic workup [8,9,94]. Though data are limited, the general approach to imaging and staging is similar to that for sinonasal squamous cell carcinoma [95].…”

Section: Sinonasal Adenocarcinomamentioning

confidence: 95%

PET/CT Imaging in Treatment Planning and Surveillance of Sinonasal Neoplasms

Akay,

Pollard,

Saad Eddin

et al. 2023

Cancers

View full text Add to dashboard Cite

Sinonasal cancers are uncommon malignancies with a generally unfavorable prognosis, often presenting at an advanced stage. Their high rate of recurrence supports close imaging surveillance and the utilization of functional imaging techniques. Whole-body 18F-FDG PET/CT has very high sensitivity for the diagnosis of sinonasal malignancies and can also be used as a “metabolic biopsy” in the characterization of some of the more common subgroups of these tumors, though due to overlap in uptake, histological confirmation is still needed. For certain tumor types, radiotracers, such as 11C-choline, and radiolabeled somatostatin analogs, including 68Ga-DOTATATE/DOTATOC, have proven useful in treatment planning and surveillance. Although serial scans for posttreatment surveillance allow the detection of subclinical lesions, the optimal schedule and efficacy in terms of survival are yet to be determined. Pitfalls of 18F-FDG, such as post-surgical and post-radiotherapy crusting and inflammation, may cause false-positive hypermetabolism in the absence of relapse.

show abstract

Section: Sinonasal Adenocarcinomamentioning

confidence: 95%

PET/CT Imaging in Treatment Planning and Surveillance of Sinonasal Neoplasms

Akay,

Pollard,

Saad Eddin

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…The role of FDG PET-CT in sinonasal carcinomas has not been as well studied as other malignancies, because these tumors are rare. However, FDG PET-CT has been shown to be of value in detecting regional lymph nodes and distant metastases [ 40 ]. Clinically relevant information may be provided by FDG PET-CT in almost 50% of patients with newly diagnosed sinonasal malignancy [ 41 ].…”

Section: Head and Neck Cancermentioning

confidence: 99%

PET-CT in Clinical Adult Oncology—V. Head and Neck and Neuro Oncology

Wiggins

Hoffman

Fine

et al. 2022

Cancers

View full text Add to dashboard Cite

PET-CT is an advanced imaging modality with many oncologic applications, including staging, assessment of response to therapy, restaging, and longitudinal surveillance for recurrence. The goal of this series of six review articles is to provide practical information to providers and imaging professionals regarding the best use of PET-CT for specific oncologic indications, and the potential pitfalls and nuances that characterize these applications. In addition, key tumor-specific clinical information and representative PET-CT images are provided to outline the role that PET-CT plays in the management of oncology patients. Hundreds of different types of tumors exist, both pediatric and adult. A discussion of the role of FDG PET for all of these is beyond the scope of this review. Rather, this series of articles focuses on the most common adult malignancies that may be encountered in clinical practice. It also focuses on FDA-approved and clinically available radiopharmaceuticals, rather than research tracers or those requiring a local cyclotron. The fifth review article in this series focuses on PET-CT imaging in head and neck tumors, as well as brain tumors. Common normal variants, key anatomic features, and benign mimics of these tumors are reviewed. The goal of this review article is to provide the imaging professional with guidance in the interpretation of PET-CT for the more common head and neck malignancies and neuro oncology, and to inform the referring providers so that they can have realistic expectations of the value and limitations of PET-CT for the specific type of tumor being addressed.

show abstract

“…2-[ 18 F]-fluorodeoxy- d -glucose whole-body positron emission tomography/computed tomography (FDG-PET/CT) and 2-[ 18 F]-fluorodeoxy- d -glucose whole-body positron emission tomography/magnetic resonance tomography (FDG-PET/MR) are well-established as part of the staging, therapy response assessment, clinical decision-making, and prognostication in patients with advanced CMM, head and neck cancer, sinonasal malignancies and particularly in SMM 2 , 12 , 15 – 17 . Limited data derived from heterogeneous sinonasal malignancy cohorts indicates a prognostic role of quantitative PET parameters for treatment response and survival outcome 15 , 18 .…”

Section: Introductionmentioning

confidence: 99%

Sinonasal mucosal melanoma treatment response assessment to immune checkpoint inhibitors using hybrid positron emission tomography imaging

Maurer,

Gstrein,

Dimitriou

et al. 2023

Sci Rep

View full text Add to dashboard Cite

The purpose of this retrospective study was to investigate response of sinonasal mucosal melanoma (SMM) patients to treatment with immune checkpoint inhibitors (ICI), using hybrid PET imaging. Fifteen SMM patients underwent hybrid PET imaging before and three months after initiation of ICI. The disease-specific survival (DSS) was calculated. Quantitative PET parameters of the primary tumor and their association with DSS and therapy response were investigated. Nine of the fifteen (60%) patients responded to ICI therapy. Patients with therapy response depicted on hybrid PET imaging had better DSS than those without (p = 0.0058). Quantitative PET parameters of the initial PET harbored no association with DSS or therapy response. However, these findings lack of sufficient statistical power and must be interpreted with caution. The first restaging PET-imaging after ICI initiation can help stratify patients with regard to DSS.

show abstract

Role of Whole-Body ¹⁸F-FDG PET/CT in Screening for Metastases in Newly Diagnosed Sinonasal Malignancies

Cited by 6 publications

References 19 publications

PET/CT Imaging in Treatment Planning and Surveillance of Sinonasal Neoplasms

PET/CT Imaging in Treatment Planning and Surveillance of Sinonasal Neoplasms

PET-CT in Clinical Adult Oncology—V. Head and Neck and Neuro Oncology

Sinonasal mucosal melanoma treatment response assessment to immune checkpoint inhibitors using hybrid positron emission tomography imaging

Contact Info

Product

Resources

About

Role of Whole-Body 18F-FDG PET/CT in Screening for Metastases in Newly Diagnosed Sinonasal Malignancies

Cited by 6 publications

References 19 publications

PET/CT Imaging in Treatment Planning and Surveillance of Sinonasal Neoplasms

PET/CT Imaging in Treatment Planning and Surveillance of Sinonasal Neoplasms

PET-CT in Clinical Adult Oncology—V. Head and Neck and Neuro Oncology

Sinonasal mucosal melanoma treatment response assessment to immune checkpoint inhibitors using hybrid positron emission tomography imaging

Contact Info

Product

Resources

About

Role of Whole-Body ¹⁸F-FDG PET/CT in Screening for Metastases in Newly Diagnosed Sinonasal Malignancies